Literature DB >> 6721576

Parathyroid hormone and calcium metabolism in generalized scleroderma. Increased PTH level and secondary hyperparathyroidism in patients with aberrant calcifications. Prophylactic treatment of calcinosis.

J Serup, H K Hagdrup.   

Abstract

Parathyroid hormone (PTH) in serum and biochemical parameters of calcium metabolism were analysed in 45 patients with systemic sclerosis. Calcification of the skin and subcutaneous tissue was assessed by X-ray examination of the hands. Analyses disclosed secondary hyperparathyroidism (increased PTH in serum, low calcium 'ion' in serum, decreased urinary excretion of calcium and phosphate), in particular in patients with calcinosis (P less than 0.05) as compared to those with no calcinosis. The duration of systemic sclerosis was longer in patients with calcinosis (P less than 0.05). The calcinosis type of systemic sclerosis is characterized by secondary hyperparathyroidism developed during the progression of the disease. A hypothesis is made regarding calcium metabolism in the early no-calcinosis (with increased synthesis of Vitamin D) and late calcinosis types. PTH may stimulate aberrant calcification. The hypothesis implicates that prophylactic treatment with Vitamin D in low dose may prevent calcinosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721576     DOI: 10.1007/BF00511062

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  14 in total

1.  A NEW ORAL ISOTOPIC TEST OF CALCIUM ABSORPTION.

Authors:  L V AVIOLI; J E MCDONALD; R A SINGER; P H HENNEMAN
Journal:  J Clin Invest       Date:  1965-01       Impact factor: 14.808

2.  SYSTEMIC SCLERODERMA, CALCINOSIS CUTIS AND PARATHYROID HYPERPLASIA.

Authors:  S M SAMUELSSON; I WERNER
Journal:  Acta Med Scand       Date:  1965-06

3.  Calcinosis cutis: its relationship to scleroderma.

Authors:  S A MULLER; L A BRUNSTING; R K WINKELMANN
Journal:  AMA Arch Derm       Date:  1959-07

Review 4.  Radioimmunoassay of human parathyroid hormone. A review with special reference to hyperparathyroidism in renal disease.

Authors:  M S Christensen
Journal:  Dan Med Bull       Date:  1979-07

5.  Morphoea with calcinosis.

Authors:  R Holmes
Journal:  Clin Exp Dermatol       Date:  1979-03       Impact factor: 3.470

6.  Bone mineral content in systemic sclerosis measured by photonabsorptiometry.

Authors:  J Serup; H Hagdrup; E Tvedegaard
Journal:  Acta Derm Venereol       Date:  1983       Impact factor: 4.437

7.  Treatment of generalized scleroderma with inhibitors of collagen synthesis.

Authors:  G Asboe-Hansen
Journal:  Int J Dermatol       Date:  1982-04       Impact factor: 2.736

8.  Radiological changes of the hands in systemic sclerosis.

Authors:  B Brun; J Serup; H Hagdrup
Journal:  Acta Derm Venereol       Date:  1983       Impact factor: 4.437

9.  Does long-term treatment with D-penicillamine alter calcium and phosphorus metabolism in patients with systemic sclerosis?

Authors:  H Hagdrup; J Serup; E Tvedegaard
Journal:  Acta Derm Venereol       Date:  1983       Impact factor: 4.437

10.  Acromegaly and vitamin D metabolism: effect of bromocriptine treatment.

Authors:  P C Eskildsen; B Lund; O H Sørensen; B Lund; J E Bishop; A W Norman
Journal:  J Clin Endocrinol Metab       Date:  1979-09       Impact factor: 5.958

View more
  2 in total

1.  Acroosteolysis and bone metabolism parameters distinguish female patients with limited systemic sclerosis with and without calcinosis: a case control study.

Authors:  Marilia M Sampaio-Barros; Lorena C M Castelo Branco; Liliam Takayama; Marco Antonio G Pontes Filho; Percival D Sampaio-Barros; Rosa Maria R Pereira
Journal:  Clin Rheumatol       Date:  2019-06-19       Impact factor: 2.980

2.  Reduced bone mass and normal calcium metabolism in systemic sclerosis with and without calcinosis.

Authors:  O Di Munno; M Mazzantini; P Massei; M Ferdeghini; N Pitaro; A Latorraca; C Ferri
Journal:  Clin Rheumatol       Date:  1995-07       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.